07.09.2005 13:00:00

Playtex Announces Thomas M. Schultz, Ph.D. as SVP Research and Development

Playtex Products, Inc. (NYSE: PYX) announced today thatThomas Schultz, Ph.D. has been named Senior Vice President, Researchand Development.

Dr. Schultz is an experienced and accomplished research anddevelopment executive in consumer products. Most recently, he was theVice President, Corporate Technology Officer of the Nu Skin Divisionof Nu Skin Enterprises, a global direct marketing, home care andnutritional goods company. Dr. Schultz began his career as a ResearchDirector at Clairol and has held positions of increasingresponsibility with Shiseido, L'Oreal, DuPont, Chanel and Procter &Gamble.

President and CEO, Neil P. DeFeo stated, "As part of our newstrategy, we plan to accelerate new product development and develop aculture of continuous innovation. Innovation is the tonic of success,and I believe it's necessary for growth. We feel that Dr. Schultz hasboth the industry experience and discipline necessary to lead our R&Dand Quality teams successfully under this new strategy."

Dr. Schultz stated, "I am pleased to be joining a company withbrands and products known for their excellent quality and strongmarket positions. I am excited about continuing the work begun by Mr.DeFeo in shaping a revitalized Playtex focused on innovation. I lookforward to working with the great group of specialists on the PlaytexResearch and Development and Quality teams."

Dr. Schultz is a graduate of New York University for each of hisdegrees including a Ph.D. and M.S. in Chemistry, and a B.A. in RussianLanguages / Chemistry-Physics.

Playtex Products, Inc. is a leading manufacturer and distributorof a diversified portfolio of Feminine Care, Infant Care and Skin careproducts, including Playtex tampons, Playtex infant feeding products,Diaper Genie, Banana Boat, Wet Ones, Baby Magic, Mr. Bubble andPlaytex gloves.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Pyxus International Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Pyxus International Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

S&P 600 SmallCap 935,46 -0,94%